Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark.
Breast Cancer Res. 2010;12(5):209. doi: 10.1186/bcr2642. Epub 2010 Sep 29.
Angiogenesis is an important component of cancer growth, invasion and metastasis. Therefore, inhibition of angiogenesis is an attractive strategy for treatment of cancer. We describe existing clinical trials of antiangiogenic agents and the challenges facing the clinical development and optimal use of these agents for the treatment of breast cancer. Currently, the most promising approach has been the use of bevacizumab, a humanized monoclonal antibody directed against the most potent pro-angiogenic factor, vascular endothelial growth factor (VEGF). Small molecular inhibitors of VEGF tyrosine kinase activity, such as sorafenib, appear promising. While, the role of sunitinib and inhibitors of mammalian target of rapamycin (mTOR) in breast cancer has to be defined. Several unanswered questions remain, such as choice of drug(s), optimal duration of therapy and patient selection criteria.
血管生成是癌症生长、侵袭和转移的一个重要组成部分。因此，抑制血管生成是治疗癌症的一种有吸引力的策略。我们描述了现有的抗血管生成药物的临床试验，以及这些药物在治疗乳腺癌的临床开发和最佳应用中面临的挑战。目前，最有前途的方法是使用贝伐单抗，一种针对最有效的促血管生成因子血管内皮生长因子（VEGF）的人源化单克隆抗体。VEGF 酪氨酸激酶活性的小分子抑制剂，如索拉非尼，似乎很有前景。而舒尼替尼和雷帕霉素（mTOR）的哺乳动物靶标抑制剂在乳腺癌中的作用还有待确定。还有一些悬而未决的问题，如药物的选择、最佳治疗持续时间和患者选择标准。
